DiaMedica Therapeutics (DMAC) Competitors $6.14 +0.77 (+14.34%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.11 -0.03 (-0.49%) As of 09/5/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. SPRY, PHVS, RCUS, ZYME, GPCR, CRMD, LENZ, SION, STOK, and MLYSShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include ARS Pharmaceuticals (SPRY), Pharvaris (PHVS), Arcus Biosciences (RCUS), Zymeworks (ZYME), Structure Therapeutics (GPCR), CorMedix (CRMD), LENZ Therapeutics (LENZ), Sionna Therapeutics (SION), Stoke Therapeutics (STOK), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Its Competitors ARS Pharmaceuticals Pharvaris Arcus Biosciences Zymeworks Structure Therapeutics CorMedix LENZ Therapeutics Sionna Therapeutics Stoke Therapeutics Mineralys Therapeutics ARS Pharmaceuticals (NASDAQ:SPRY) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation. Which has more risk & volatility, SPRY or DMAC? ARS Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Do analysts recommend SPRY or DMAC? ARS Pharmaceuticals currently has a consensus price target of $32.50, indicating a potential upside of 222.74%. DiaMedica Therapeutics has a consensus price target of $12.33, indicating a potential upside of 100.87%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe ARS Pharmaceuticals is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, SPRY or DMAC? ARS Pharmaceuticals has higher revenue and earnings than DiaMedica Therapeutics. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$89.15M11.16$8M-$0.49-20.55DiaMedica TherapeuticsN/AN/A-$24.44M-$0.69-8.90 Do insiders and institutionals believe in SPRY or DMAC? 68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 33.5% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor SPRY or DMAC? In the previous week, ARS Pharmaceuticals had 8 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 25 mentions for ARS Pharmaceuticals and 17 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.38 beat ARS Pharmaceuticals' score of 1.19 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SPRY or DMAC more profitable? DiaMedica Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -42.74%. ARS Pharmaceuticals' return on equity of -21.85% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals-42.74% -21.85% -15.88% DiaMedica Therapeutics N/A -78.99%-69.94% SummaryARS Pharmaceuticals beats DiaMedica Therapeutics on 12 of the 16 factors compared between the two stocks. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$277.57M$3.12B$5.76B$9.91BDividend YieldN/A2.29%6.71%4.52%P/E Ratio-8.9020.9775.5426.08Price / SalesN/A290.04480.4288.28Price / CashN/A44.9736.9659.01Price / Book6.469.8611.446.09Net Income-$24.44M-$53.47M$3.28B$266.14M7 Day Performance7.53%2.92%0.96%0.44%1 Month Performance30.08%9.83%7.83%4.55%1 Year Performance52.36%15.97%62.65%26.15% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics2.1611 of 5 stars$6.14+14.3%$12.33+100.9%+59.5%$277.57MN/A-8.9020Trending NewsAnalyst DowngradeInsider TradeGap UpHigh Trading VolumeSPRYARS Pharmaceuticals2.8797 of 5 stars$11.62-9.6%$31.00+166.8%-14.3%$1.15B$89.15M-23.7190News CoveragePositive NewsAnalyst ForecastHigh Trading VolumePHVSPharvaris2.9743 of 5 stars$21.65-5.2%$35.60+64.4%+20.7%$1.13BN/A-6.4430News CoverageRCUSArcus Biosciences2.2051 of 5 stars$10.60-0.1%$21.14+99.6%-24.4%$1.13B$258M-3.34500News CoveragePositive NewsZYMEZymeworks0.1062 of 5 stars$14.81-0.2%N/AN/A$1.11B$76.30M-15.27460GPCRStructure Therapeutics2.7742 of 5 stars$19.30+0.8%$75.71+292.3%-42.5%$1.11BN/A-18.38136Positive NewsCRMDCorMedix3.3437 of 5 stars$14.83+3.3%$17.33+16.9%+117.5%$1.11B$43.47M19.7730Positive NewsShort Interest ↑LENZLENZ Therapeutics1.6948 of 5 stars$38.63+1.1%$49.60+28.4%+75.8%$1.10BN/A-20.33110Positive NewsSIONSionna TherapeuticsN/A$24.62-4.3%$38.50+56.4%N/A$1.09BN/A0.0035News CoverageAnalyst ForecastInsider TradeSTOKStoke Therapeutics4.447 of 5 stars$19.76-0.1%$25.57+29.4%+36.5%$1.08B$36.56M23.25100News CoverageInsider TradeMLYSMineralys Therapeutics1.5085 of 5 stars$15.48+1.7%$34.40+122.2%+191.5%$1.03BN/A-4.3528News CoverageAnalyst Forecast Related Companies and Tools Related Companies ARS Pharmaceuticals Alternatives Pharvaris Alternatives Arcus Biosciences Alternatives Zymeworks Alternatives Structure Therapeutics Alternatives CorMedix Alternatives LENZ Therapeutics Alternatives Sionna Therapeutics Alternatives Stoke Therapeutics Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: Musk’s IRS move could blindside your retirementElon Musk just made a bold financial move — one that some say could hit retirements harder than any recession....American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DMAC Stock Alerts